In this study we compared the ability of free-and liposome-incorporated murine recombinant gamma interferon (rIFN-'y) to enhance peritoneal macrophage H202 release and antitoxoplasma activity in vitro.
rIFN-'y was efficiently (37 to 47%) incorporated into multilamellar vesicles composed of phosphatidylgycerol/ cholesterol in a 2:1 molar ratio. The amount of rIFN-y incorporated into multilamellar vesicles and added to macrophages (0.1 to 1,000 U/ml) was quantitated with [3H]rIFN-,y. The concentration of liposomal rIFN--y required to enhance macrophage H202 release (1 U/mI) and maximally inhibit Toxoplasma gondii growth (10 U/mI) was one-tenth the concentration required for free rIFN-'y (10 and 100 U/ml, respectively). This increase in potency was observed in both thioglycolate-elicited and resident peritoneal macrophages. Control liposomes containing encapsulated buffer had no effect on the potency of free rIFN--y. The duration of macrophage activation induced by 24 h of liposomal rIFN-y treatment was also considerably longer than that induced by free rIFN-y (2 days versus < 1 day). These data indicate that liposomal rIFN-,y is more active than free rIFN-y as an inducer of macrophage microbicidal properties in vitro. This enhanced activity, combined with the potential for selective delivery of liposomal rIFN--y to phagocytic cells in vivo, may improve the therapeutic efficacy of rIFN-y in infections characterized by parasitization of phagocytes.
Toxoplasma gondii has emerged as a formidable opportunistic pathogen of the central nervous system in patients with the acquired immune deficiency syndrome (27) . Conventional treatment of toxoplasmic encephalitis with pyrimethamine and sulfadiazine is limited by toxicity (14, 27, 33) and a lack of drug activity against the latent cystic form of the parasite, resulting in an unacceptably high relapse rate if therapy is discontinued (14, 23, 27, 33) . These limitations have prompted the search for alternative therapeutic strategies. Considerable recent interest has focused on the potential use of immunoregulatory cytokines to restore or augment the cell-mediated immune response to infection (6, 29, 39) .
Mononuclear phagocytes (monocytes and macrophages) are critical components of the immune response to infection with T. gondii and other intracellular pathogens (16, 29) . The ability of macrophages to kill intracellular pathogens depends on their state of activation; nonactivated cells permit unrestricted parasite growth, whereas cells exposed to macrophage-activating factors (MAFs) are able to kill parasites or inhibit their growth (29) . The major endogenously produced MAF is gamma-interferon (IFN--y), a glycoprotein secreted predominantly by sensitized T cells in response to antigen (29) . The recent availability of large quantities of purified IFN--y through recombinant DNA technology (13) has generated interest in its use as a therapeutic agent in infections characterized by parasitization of macrophages (29, 31, 32) . The therapeutic potential of IFN-y may be limited, however, by rapid clearance from the circulation (31, 42) , a brief duration of activating effect on tissue macrophages (31) , toxicity (3, 38, 41) , and an inability to * Corresponding author.
selectively deliver the molecule to the appropriate effector cells.
A potential means of overcoming these limitations is the use of liposomes (phospholipid vesicles) as a carrier system for IFN--y. Liposomes are avidly phagocytosed by monocytes and macrophages, resulting in increased delivery of liposome-incorporated substances to these cells (15, 17) . This enhanced drug delivery has markedly improved the therapeutic index of certain antibiotics in animal models of infectious diseases (24) , particularly when macrophages are a major reservoir of infection (e.g., leishmaniasis [1] ), and in selected patients with disseminated fungal infections (25) . Moreover, incorporation of crude MAFs (8, 19, 37) , recombinant IFN--y (rIFN--y; 20, 21), or muramyl dipeptides (10, 22, 40) into liposomes has been shown to augment the ability of these MAFs to induce macrophage-mediated lysis of neoplastic and herpesvirus-infected target cells in vitro (19, 20, 21, 37, 40) and in vivo (8, 10, 22 30 mM glycine, 30 mM NaCl, 10 mM HEPES [N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid], pH 6.5) was added to the dried lipid film, and the tube was flushed with argon. The mixture was then gently vortexed for 20 min. Unincorporated rIFN--y was separated from the MLV by four centrifugations at 20,000 x g for 30 min with buffer washes. Control liposomes were prepared in the same manner with rIFN--y-free buffer. The amount of lipid in the final liposome preparations was determined by phosphate analysis (2) . The efficiency of rIFN--y incorporation was calculated as a percentage of the initial amount added and as the "entrapped volume" of aqueous phase in microliters per micromole of total lipid. The latter measure is independent of lipid recovery and is therefore preferred when comparing the incorporation efficiency obtained by different methods of liposome preparation or with different incorporated substances. The incorporation of rIFN--y was compared with that of [ 10 times more rIFN--y becomes incorporated in MLV than can be explained on the basis of passive entrapment in the aqueous space.
Macrophage H202-releasing capacity induced by free or liposomal rIFN--y. In initial experiments, we compared the ability of free and liposomal rIFN--y (0.1 to 1,000 U/ml) to prime thioglycolate-elicited macrophages for phorbol 12-myristate 13-acetate-triggered H202 release. Macrophages were incubated for 2 days prior to assay with free rIFN-y, liposomal rIFN--y, or free rIFN--y plus control liposomes containing encapsulated buffer (the amount of control liposomes added with free rIFN--y equalled the amount in the corresponding concentration of liposomal rIFN-y). The liposomal lipid concentrations incubated with the cells ranged from approximately 1.0 pmol/ml (0.1 U/ml) to 10 nmol/ml (1,000 U/ml).
The results of two experiments, representative of five total experiments, are shown in Fig. 2 . In comparing the concentration-response curves for the two rIFN--y forms, liposomal rIFN--y was found to be approximately 10-fold more potent than free rIFN--y as an activator of macrophage H202 release. The minimum concentration of liposomal rIFN--y required to increase H202 release was 1.0 U/ml, compared with 10.0 U/ml for free rIFN--y (P < 0.05). Moreover, near-maximal stimulation of H202 release was induced by 10 U of liposomal rIFN--y per ml, whereas 100 U of free rIFN--y per ml was required (P < 0.05). Control liposomes did not increase the potency of free rIFN--y (Fig. 2) . The protein contents of free and liposomal rIFN--y-treated monolayers were not significantly different (not shown). Of note, however, is that liposomal rIFN--y did not significantly raise the maximal H202-releasing capacity of macrophages above that achieved with higher concentrations of free rIFN--y (Fig. 2) response to phorbol 12-myristate 13-acetate correlates with their ability to inhibit T. gondii (30), we next determined whether liposomal rIFN--y was a more potent inducer of macrophage antitoxoplasma activity. Liposomal rIFN--y was 10-fold more potent than free rIFN--y in four consecutive experiments (P < 0.05) (Fig. 3 ). Control liposomes again had no effect on the activating potency of free rIFN-y (Fig. 3) .
Additional control experiments were performed to assess whether the increased potency of liposomal rIFN-y was due to a direct cytotoxic effect of liposomal rIFN--y on extracellular T. gondii. In these experiments, macrophages were washed extensively to remove liposomal rIFN-y prior to infection with T. gondii. Removal of liposomal rIFN--y in this manner did not alter the experimental results (data incorporated into Fig. 3 ). The ability of resident murine peritoneal macrophages to be activated by liposomal rIFN--y was also studied. Liposomal rIFN--y was also a 10-fold more potent inducer of antitoxoplasma activity in resident macrophages than free rIFN-y (Fig. 4) .
Duration of macrophage activation induced by free or liposomal rIFN--y. To further assess the activity of liposomal rIFN-y, we compared the duration of macrophage activation induced by free or liposomal rIFN--y. Thiogycolate-elicited macrophages were treated with 1,000 U of free or liposomal rIFN--y per ml for 24 h, washed, and assayed for antitoxoplasma activity immediately after washing and 1, 2, or 3 days thereafter. An rIFN--y concentration of 1,000 U/ml was chosen because this concentration of either free or liposomal rIFN--y induced maximal activation after 24 h (Fig. 3) . Liposomal rIFN--y induced a more prolonged state of activation (Table 1) . One day after removal of free IFN--y, macrophage antitoxoplasma activity was not greater than that of control cells, whereas liposomal rIFN--y-treated cells exhibited half-maximal antitoxoplasma activity 2 days after washing. DISCUSSION These studies demonstrate that liposome incorporation enhances the potency and duration of the activating effect of rIFN--y on macrophage H202 release and antitoxoplasma capacity in vitro. This was observed in both resident and elicited (inflammatory) macrophages, indicating that the effect was not restricted to a particular macrophage subset or dependent on an earlier priming signal. The enhanced duration of activation induced by liposomal IFN--y appears to be related to its greater potency. When equipotent doses of free and liposomal IFN--y were compared (e.g., 1,000 U of free and 100 U of liposomal IFN--y per ml) the duration of action was similar (data not shown). The mechanisms responsible for the enhanced activity of liposomal rIFN-y are uncertain and will require further investigation of liposomal rIFN--y uptake and receptor binding. The possibility that the liposome preparations were contaminated with a coactivating stimulus, such as bacterial endotoxin (43) , is unlikely given that the liposomal rIFN--y preparations did not contain detectable endotoxin in the Limulus amebocyte lysate assay when tested at concentrations higher than those used in the experiments and that control liposomes failed to enhance the activity of free rIFN--y. Possible mechanisms for the enhanced activity of liposomal rIFN-y include more efficient interaction with plasma membrane IFN-,y receptors as a result of adsorption and endocytosis of liposomes by macrophages (15, 17) or binding of endocytosed IFN-y to a novel intracellular receptor, as has been postulated by Poste and others (9, 18, 19, 37) . The latter hypothesis, however, has (7, 29) to the net negatively charged lipid bilayers. These observations suggest that the smaller difference in potency between free and liposomal rIFN--y that we observed is explained, in part, by the method used to quantitate the amount of liposome-incorporated rIFN-y.
The lipid composition of our MLV, however, was different from that of previous investigators: egg-phosphatidylcholine and beef brain phosphatidylserine in a molar ratio of 7:3 (19, 21) . We did not use phosphatidylserine since this phospholipid has been shown to block IFN--y-induced activation of macrophage microbicidal properties (11, 12) . Nevertheless, we have incorporated [3H]rIFN--y into MLV composed of phosphatidylcholine/phosphatidylserine (7:3) and have found the entrapped volume of rIFN--y to be 39 ± 6 (standard error) ,Il/,umol of lipid (n = 3). This entrapped volume of IFN--y is at least 10-fold higher than that previously estimated for MLV of this composition (2.5 jdl/4mol of lipid) (19) (20) (21) . The greater association of rIFN--y with phosphatidylcholine/phosphatidylserine MLV (39 ,ul/dmol) than with phosphatidylglycerol/cholesterol MLV (15 ,ul/,umol) may be due to higher negative-charge density in phosphatidylcholine/phosphatidylserine liposomes.
In summary, incorporation of rIFN--y into MLV enhances its ability to activate tissue-derived macrophage microbicidal functions in vitro. This effect, combined with the potential for more selective delivery of liposomal rIFN--y to phagocytic effector cells in vivo, may enhance the efficacy of rIFN--y for the treatment of diseases caused by intracellular pathogens such as T. gondii. This may be of particular benefit in the current epidemic of toxoplasmic encephalitis in patients with the acquired immune deficiency syndrome. These preliminary observations justify further exploration of the antimicrobial activity of liposomal rIFN--y in vivo.
